Experts

Justin Mandala, MD, MPH

Technical Advisor, Prevention of Mother-to-Child Transmission (PMTCT) of HIV

Areas of expertise

  • Prevention of mother-to-child transmission (PMTCT)
  • HIV/AIDS
  • HIV prevention

Projects & Resources

  • In collaboration with the Government of Zambia, the Ministry of Health and the Ministry of Community Development and Mother and Child Health, the Zambia Care and Treatment Partnership (ZPCT Bridge, previously ZPCT II) is being conducted in six provinces to strengthen the national health system by maximizing access, equity, quality and sustainability in the delivery of comprehensive HIV/AIDS services.

  • The Global HIV/AIDS Initiative Nigeria (GHAIN) was designed to support the Government of Nigeria in reducing the impact of HIV/AIDS and tuberculosis (TB) in select states by strengthening and expanding HIV/AIDS services.

Published Research

  • Pre-exposure prophylaxis for HIV infection among African women
    Van Damme L. Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malaheleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak’Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D on behalf of the FEM-PrEP study group
    New England Journal of Medicine. 2012; 367 (5): 411-22

    Pre-exposure prophylaxis with antiretroviral drugs has been effective in the prevention of HIV infection in some trials but not in others. This randomized, double-blind, placebo-controlled trial assigned 2,120 HIV-negative women in Kenya, South Africa, and Tanzania to receive either a combination of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) or placebo once daily to assess the effectiveness of TDF-FTC in preventing HIV acquisition and to evaluate safety. The study was stopped early, on April 18, 2011, because of lack of efficacy. Prophylaxis with TDF-FTC did not significantly reduce the rate of HIV infection and was associated with increased rates of side effects, as compared with placebo. Despite substantial counseling efforts, drug adherence appeared to be low.

  • Pregnancy and contraceptive use among women participating in the FEM-PrEP trial
    Callahan R, Nanda K, Kapiga S, Malahleha M, Mandala J, Ogada T, Van Damme L, Taylor D, FEM-PrEP study group.
    J Acquir Immune Defic Syndr 2015 Feb; 68 (2): 196-203. [Journal Impact Factor: 4.394]

    Pregnancy among participants in HIV prevention clinical trials continues to present a challenge. This study found that women who adopted an injectable contraceptive at the beginning of the trial were more likely to adhere to study product than women using combined oral contraceptives. HIV prevention trials should consider requiring long-acting methods, including injectables, for study participation.

Explore More Related to Justin Mandala, MD, MPH